ANRIL silencing attenuated atherosclerosis in macrophage-derived foam cells and in ApoE−/− mouse models of atherosclerosis and promoted the reversal by macrophage reverse cholesterol transport (mRCT)—suggesting a potential therapeutic modality in targeting ANRIL for treating atherosclerosis. This evidence concerns the gene CDKN2B-AS1 and atherosclerosis.